28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Both MSS and Activity sessions appear to be effective and appropriate therapies for people with dementia. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study aims to systematically evaluate the efficacy of Pet robot intervention (PRI) for people with dementia. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
On average, participants were aged 63 years and had 16 years of education. 5 key findings →
Design: randomized controlled trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The sample consisted predominantly of women (79% in the intervention group, 69% in the control group), with daughters forming the largest caregiver subgroup (66.6% and 52.4%, respectively). 5 key findings →
Design: randomized controlled trial Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 110 participants (mean [SD] age, 67.9 [4.6] years; 68 female [61.8%]) were randomized to the experimental group (n = 55) and the sham group (n = 55) and included in the intention-to-treat analysis. 5 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Personalized repetitive transcranial magnetic stimulation (rTMS) of the precuneus (PC) is emerging as a new non-invasive therapeutic approach in treating Alzheimer’s disease (AD). 3 key findings →
Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study examined the combined effects of StrongerMemory program (brain exercises involving reading, writing, and math) and weekly social engagement on cognitive, behavioral, and emotional outcomes in older adults with subjective cognitive decline (SCD). 4 key findings →
Design: randomized controlled trial Participants: 50 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Collectively, plasma biomarker findings in the low p-tau217 subgroup were more robust than in the mITT population. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Evidence from a limited number of randomised controlled intervention trials (RCTs) have shown that a Mediterranean dietary pattern may reduce the risk of cognitive decline and enhance cognitive function among healthy older adults. 3 key findings →
Participants: 137 Evidence: high
Full summary, score breakdown and related studies → Original source
The pathophysiological mechanism of freezing of gait (FoG) has been linked to executive dysfunction. 3 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
No definitive conclusions about the superiority of any of the tested interventions can be made. 3 key findings →
Participants: 259 Evidence: high
Full summary, score breakdown and related studies → Original source
Mean age of completers (n = 30) was 73.5 years and mean Mini-Mental Status Examination (MMSE) score was 22.5. 3 key findings →
Design: open-label trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
Combined rTMS and cognitive training may improve the cognitive status of AD patients, with TMS-induced cortical plasticity at baseline serving as predictor of therapeutic outcome for this intervention, and potential mechanism of action. 2 key findings →
Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source
BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). 3 key findings →
Participants: 18 Evidence: high
Full summary, score breakdown and related studies → Original source
At the end of the study cognitive function had deteriorated among those in the placebo group. 4 key findings →
Participants: 725 Evidence: high
Full summary, score breakdown and related studies → Original source
Cholinesterase inhibitors and memantine are able to stabilize or slow decline in cognition, function, behavior, and global change. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care. 4 key findings →
Participants: 93 Evidence: high
Full summary, score breakdown and related studies → Original source
The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. 1 key finding →
Design: clinical trial Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source
AC-1202 was compared to Placebo in several population groups, including: intention-to-treat (ITT), per protocol, and dosage compliant groups. 5 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source
Donepezil was well tolerated and most adverse events were mild. 5 key findings →
Participants: 22 Evidence: high
Full summary, score breakdown and related studies → Original source
We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. 4 key findings →
Participants: 497 Evidence: high
Full summary, score breakdown and related studies → Original source
This is the first report describing Aβ-PF species captured by lecanemab in human CSF and supporting that Lec-PF is correlated with neurodegeneration in AD and may explain the mechanism of the clinical effect of lecanemab. 3 key findings →
Participants: 163 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with early AD show heterogeneity in disease progression, which increases when stratifying on risk factors associated with progression. 3 key findings →
Participants: 302 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hormonal changes associated with the menopausal transition and postmenopause have the potential to influence processes linked to Alzheimer's disease symptoms and pathogenesis, but effects of menopause on Alzheimer risk can be addressed only indirectly. 4 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →